Bilirubin (µmol/L) · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review
Proportion of infants who required exchange transfusion · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
Intravenous fluid supplementation may leads to lower proportion of infants who required exchange transfusion compared with no fluid supplementation (low certainty).
1 finding from 1 review
Frequency of breastfeeding per day · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review
Number of infants with abnormal neurological signs · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review
Bilirubin (µmol/L) · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review
Rate of change in bilirubin (μmol/L/hour): during the first 4 hours of admission · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review
Eradication of P aeruginosa from the respiratory tract: number of participants testing negative for P aeruginosa at 3 months and remaining free until 15 months · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Mean weight‐for‐age z‐score · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Frequency of infective pulmonary exacerbations: number of participants experiencing an exacerbation · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Intravenous ceftazidime with tobramycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with oral ciprofloxacin (high certainty).
1 finding from 1 review
Isolation of other micro‐organisms from the respiratory tract: number of participants isolating other micro‐organisms within the 15‐month · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Intravenous ceftazidime with tobramycin leads to higher isolation of other micro‐organisms from the respiratory tract:… compared with oral ciprofloxacin (high certainty).
1 finding from 1 review
Adverse effects of antibiotics · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Intravenous ceftazidime with tobramycin probably leads to lower adverse effects of antibiotics: compared with oral ciprofloxacin (moderate certainty).
1 finding from 1 review
Change in disability score · children with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Muscle strength · children with SMA types II and III
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low
Acquiring the ability to stand or walk · children with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in quality of life · children with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in pulmonary function · children with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time from birth until death or full‐time ventilation · children with SMA types II and III
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Low
Adverse events related to treatment · children with SMA types II and III
1 finding from 1 review
no estimate extracted
1 study · 9 participants
Very low